Everest Medicines Reports Promising First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16
核心洞察
Everest Medicines (搜索) presented first-in-human clinical trial data for EVM16, a personalized mRNA cancer vaccine, at AACR 2026, demonstrating favorable safety profile with no dose-limiting toxicities observed across nine patients.
EVM16 elicited strong neoantigen-specific T cell responses in 8 of 9 patients with a dose-dependent trend, with one gastroesophageal junction cancer (搜索) patient achieving confirmed partial response after failing three prior therapies.
The vaccine uses Everest's proprietary AI-based algorithm EVER-NEO-1 to predict patient-specific tumor neoantigens (搜索) and employs lipid nanoparticle delivery to activate tumor-killing T cells.
Everest Medicines (搜索) announced positive first-in-human clinical trial results for EVM16, its proprietary personalized mRNA cancer vaccine, at the 2026 American Association for Cancer Research Annual Meeting. The data demonstrated favorable safety, robust immunogenicity, and promising preliminary efficacy in patients with advanced solid tumors (搜索), supporting continued clinical development of this novel immunotherapy approach.
Clinical Trial Design and Patient Population
The EVM16CX01 study (NCT06541639) is a first-in-human, dose-escalation, and expansion trial conducted jointly by Peking University Cancer Hospital (搜索) and Fudan University Shanghai Cancer Center. The study follows a 3+3 dose-escalation design across three dose levels: 0.1 mg, 0.3 mg, and 1.0 mg.
Eligible patients included those with advanced or recurrent solid tumors who had failed standard of care and possessed at least one measurable target lesion. The treatment protocol involved patients receiving 2 doses of EVM16 monotherapy once every two weeks, followed by combination therapy with EVM16 and the PD-1 (搜索) inhibitor tislelizumab.
As of December 7, 2025, nine patients had been enrolled, with three patients at each dose level. All patients completed the dose-limiting toxicity assessment and underwent at least one efficacy evaluation.
Safety and Tolerability Profile
The safety results showed no dose-limiting toxicities across all dose levels. While all patients experienced at least one investigational product-related adverse event, these were all Grade ≤ 2 and resolved spontaneously. This favorable safety profile supports the continued development of EVM16 in cancer patients.
Immunogenicity and Efficacy Signals
EVM16 demonstrated robust immunological activity, eliciting strong neoantigen-specific T cell responses in 8 of 9 patients. Importantly, these immune responses showed a dose-dependent trend, indicating consistent immune activation capability across the tested dose range.
Preliminary efficacy signals were observed in heavily pretreated patients. A gastroesophageal junction cancer (搜索) patient who had failed three prior lines of systemic therapy achieved a confirmed partial response with a progression-free survival of 126 days. Additionally, two patients achieved stable disease.
Other notable responses included a non-small cell lung cancer (搜索) patient who failed three prior therapies achieving a progression-free survival of 88 days, and an esophageal squamous cell carcinoma (搜索) patient who has been followed for 112 days without disease progression after failing three prior treatment lines.
Technology Platform and Mechanism
EVM16 represents Everest's first in-house developed personalized mRNA cancer vaccine, powered by the company's proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1. This algorithm analyzes patient-specific tumor mutations to identify highly immunogenic neoantigens (搜索) and supports the design of personalized mRNA vaccine candidates.
The vaccine is designed to encode dozens of tumor neoantigens (搜索) and uses a lipid nanoparticle delivery system to efficiently deliver neoantigen-encoded mRNA in vivo. This approach activates neoantigen-specific tumor-killing T cells and inhibits tumor growth.
Expert Commentary
Professor Shen Lin, Director of the Gastrointestinal Oncology Department at Beijing Cancer Hospital and Chair of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology, commented on the results: "As a novel personalized mRNA cancer vaccine, EVM16 has demonstrated encouraging clinical development potential in its first-in-human clinical trial. The data show a favorable safety and tolerability profile in patients with advanced solid tumors (搜索), with no dose-limiting toxicities observed."
He emphasized the clinical significance: "While immunotherapies, including checkpoint inhibitors, have transformed the treatment landscape in selected tumor types, most patients, particularly those with heavily pretreated advanced solid tumors (搜索), still represent a significant unmet medical need. Personalized mRNA cancer vaccines represented by EVM16 may help expand the population benefiting from immunotherapy and provide additional treatment options."
Company Perspective and Platform Development
Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines (搜索), highlighted the broader implications: "The favorable safety, tolerability, immunogenicity, and preliminary efficacy results for EVM16 provide initial evidence of its therapeutic potential and support the clinical value of our in-house mRNA platform."
Everest Medicines (搜索) has established an end-to-end integrated platform spanning antigen design, mRNA sequence optimization, lipid nanoparticle targeted delivery, and scalable manufacturing. The EVER-NEO-1 algorithm incorporates iterative learning capabilities designed to continuously improve neoantigen prediction accuracy and selection efficiency.
Market Context
According to Grand View Research data cited in the announcement, the global personalized cancer vaccine market is projected to reach $1.45 billion by 2030, with a compound annual growth rate of 44.86% from 2025 to 2030. This represents significant commercial potential for successful personalized cancer vaccine platforms.
The positive first-in-human data for EVM16 positions Everest Medicines (搜索) as a key player in the emerging personalized mRNA cancer vaccine space, with the potential to address significant unmet medical needs in oncology through its AI-driven, personalized approach to cancer immunotherapy.